AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-III HARMONIZE trial in Patients with Hyperkalaemia

 AstraZeneca Reports Results of Lokelma (sodium zirconium cyclosilicate) in P-III HARMONIZE trial in Patients with Hyperkalaemia

Shots:

  • The global P-III HARMONIZE involves assessing of Lokelma (5/10mg) vs PBO in 267 patients with hyperkalaemia in Japan, Korea, Taiwan and Russia across 47 locations
  • P-III HARMONIZE Results: @48 hrs.: Achieved normokalaemia (mean K level 3.5-5.0 mEq/L) 93%; safety was consistent with previous trials. These results will support its registration in Japan, Korea, Taiwan and Russia, are presented at ASN Kidney Week,2018
  • Lokelma is currently approved in adults for hyperkalemia in the US & EU. In 2015, AZ acquired Lokelma from ZS pharma

Click here to read full press release/ article | Ref: AstraZeneca | Image: Investomania

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post